Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMP Regimen for Untreated Nodal TFH Cell Lymphoma
NCT05958719Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in follicular T-cell lymphoma (FTCL), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Mar 2023; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
follicular T-cell lymphoma (FTCL)
Beyond the preview
Go deeper on NCT05958719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05958719.